REG - Proteome Sciences - Director/PDMR Shareholding

Proteome SciencesAnnouncement

27/07/2018 12:25

RNS Number : 0342W
Proteome Sciences PLC
27 July 2018
 


27 July 2018
 
 
 
 
 
Proteome Sciences plc
("Proteome Sciences" or the "Company")
 
Director/PDMR Shareholding
 
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 25 July 2018, it purchased 171,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 2.85p per Ordinary Share (the "Purchase"). Following the purchase, Vulpes has a total direct and indirect interest in 55,388,431 equivalent to 18.76% of Proteome Sciences' total issued share capital.
 
The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes Investment Management and the Company, he now has an interest in 55,388,431 Ordinary Shares of the Company representing 18.76% of the issued share capital of the Company.
 
The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
 



1.     


Details of the person discharging managerial responsibilities/person closely associated




a)


Name:


Martin Diggle




 


Reason for the notification




a)


Position/status:


Non-Executive Director




b)


Initial notification/Amendment:


Initial Notification




 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name:


Proteome Sciences Plc




b)


LEI:


213800Q62ICXANKU2986




 


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument:
Identification code:


Ordinary Shares of 1p nominal value
GB0003104196




b)


Nature of the transaction:


Purchase of Ordinary Shares




c)


Price(s) and volume(s):


 



Price(s)


Volume(s)




2.85


171,000








d)


Aggregated information:
·    Aggregated volume:
·    Price:


Single transaction as in 4 c) above



Average Price


Volume(s)




2.85


171,000








e)


Date of the transaction:


25 July 2018




f)


Place of the transaction:


London Stock Exchange, AIM (XLON)



 
For further information:
 



Proteome Sciences plc




Dr Jeremy Haigh, Chief Executive Officer


Tel: +44 (0)20 7043 2116




Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer


















finnCap Limited (Nominated Adviser & Broker) 




Geoff Nash/Hannah Boros (Corporate Finance)
Abigail Wayne (Broking)


Tel: +44 (0)20 7220 0500
 
 



 
About Proteome Sciences plc. (www.proteomics.com)
 
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
 
Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHSESFFWFASEEW